GW Pharmaceuticals plc(GWPH)- NASDAQ
  • Tue, Aug. 9, 10:23 AM
    • GW Pharmaceuticals (GWPH +0.6%) FQ3 results (₤): Revenues: 2.3M (-73.3%); R&D Expense: 25.6M (+23.1%); SG&A: 5.6M (+86.7%); Operating Loss: (18.4M) (+25.8%); Net Loss: (12.2M) (+43.0%); Loss Per Share: (0.05) (+44.4%); Quick Assets: 191.2M (-18.6%); CF Ops: (57.2M) (-137.3%).
    • No guidance given.
    | Tue, Aug. 9, 10:23 AM | 1 Comment
  • Tue, Aug. 9, 7:15 AM
    • GW Pharmaceuticals (NASDAQ:GWPH): FQ3 EPS of -₤0.05
    • Revenue of ₤2.34M (-72.9% Y/Y)
    • Shares -1.94% PM.
    • Press Release
    | Tue, Aug. 9, 7:15 AM | 2 Comments
  • Mon, Aug. 8, 5:30 PM
  • Tue, Jul. 12, 5:39 PM
    • GW Pharmaceuticals (NASDAQ:GWPH) announces its plan to sell $150M of American Depositary Shares (ADSs) in a U.S. public offering. Underwriters over-allotment will be an additional $22.5M of ADSs. Price and terms have yet to be announced.
    • Shares are down 3% after hours on modest volume.
    • Update: On July 13, the company announced that the offering is 2.8M ADSs at $90 per ADS generating gross proceeds of $252M. Each ADS represents 12 ordinary shares. Underwriters over-allotment is an additional 420K ADSs. Closing date is July 18. Shares are down 6% on more than triple normal volume.
    • Update: On July 18, GW announced that it raised $289.8M. The underwriters over-allotment was fully exercised.
    | Tue, Jul. 12, 5:39 PM | 3 Comments
  • Tue, Jul. 12, 5:36 PM
    • Top gainers, as of 5.25 p.m.: JUNO +27.7%. KITE +8.9%. RWLK +7.3%. CBK +5.3%. WB +2.2%.
    • Top losers, as of 5.25p.m.: AIR -10.2%. SGY -3.9%. CHSP -3.2%. GWPH -3.2%. INAP -3.1%.
    | Tue, Jul. 12, 5:36 PM | 3 Comments
  • Fri, Jul. 1, 10:13 AM
    • Aldyra Therapeutics (NASDAQ:ALDX) initiated with Buy rating and $16 (158% upside) price target by Stifel Nicolaus.
    • Shire plc (NASDAQ:SHPG) re-initiated with Buy rating and 6300p (36% upside) price target by Goldman Sachs.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $16 (129% upside) price by Baird.
    • Ultragenyx (NASDAQ:RARE) initiated with Buy rating and $72 (41% upside) price target by Bank of America.
    • NantHealth (NASDAQ:NH) initiated with Buy rating and $17 (36% upside) price target by Canaccord Genuity. First Analysis rates it Overweight with an $18 (44% upside) price target. Cowen and Company rates it Outperform with a $19 (52% upside) price target.
    • Clearside Biomedical (Pending:CLSD) initiated with Buy rating and $13 (84% upside) price target by Stifel Nicolaus. Cowen & Company rates it Outperform. Wedbush rates it Outperform with $28 (296% upside) price target.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Sell rating and $40 (57% downside risk) price target by Janney Capital.
    | Fri, Jul. 1, 10:13 AM | 3 Comments
  • Mon, Jun. 27, 9:13 AM
    | Mon, Jun. 27, 9:13 AM
  • Mon, Jun. 27, 8:14 AM
    • GW Pharmaceuticals (NASDAQ:GWPH) is up 18% premarket on robust volume in response to its announcement of positive top-line data from a Phase 3 clinical trial assessing lead product candidate, Orphan Drug-tagged Epidiolex (cannabidiol), for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
    • The study achieved its primary endpoint of a statistically valid reduction in the monthly frequency of drop seizures over the 14-week treatment period compared to placebo (p=0.0135).
    • The trial randomized 171 LGS patients 1:1 to receive either 20 mg/kg/day of Epidiolex (n=86) or placebo (n=85) added to their current anti-epileptic drug treatment. The median baseline drop seizure frequency per month was 74, which was reduced 44% in the Epidiolex arm compared to a 22% reduction for placebo. Drop seizures were defined as atonic (brief lapse in muscle tone), tonic (body stiffens) and tonic-clonic (muscles stiffen accompanied by jerky movements) seizures involving the entire body, trunk or head that led or could have led to a fall, injury, slumping in a chair or hitting the patient's head on a surface.
    • CEO Justin Glover says, "We are delighted to announce positive results in this Phase 3 trial of Epidiolex in patients with Lennox-Gastaut syndrome, and particularly pleased that this result is consistent with our recent Phase 3 pivotal data for Epidiolex in Dravet syndrome. We now look forward to advancing Epidiolex towards the submission of an NDA with the FDA in the first half of 2017."
    • Full results will be presented at future medical conferences and will be submitted for publication.
    • Results from a second Phase 3 study in LGS should be released in Q3.
    | Mon, Jun. 27, 8:14 AM | 2 Comments
  • Tue, Jun. 21, 8:18 AM
    • GW Pharmaceuticals (NASDAQ:GWPH) edges up 3% premarket on light volume in response to its announcement that it has formalized a fourth target indication, infantile spasms (IS), for lead product candidate Epidiolex (cannabidiol). The FDA has designated Epidiolex an Orphan Drug for the treatment of IS. A two-part Phase 3 study should commence in Q4.
    • IS is an epilepsy-type of seizure in infancy and childhood known as West syndrome. The condition constitutes 2% of childhood epilepsy cases. It affects 2K - 4K American kids each year. The long-term prognosis is poor.
    • Epidiolex is currently under development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex.
    | Tue, Jun. 21, 8:18 AM
  • Fri, Jun. 3, 8:01 AM
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Buy rating and $181 (87% upside) price target by Cantor Fitzgerald.
    • Bluebird bio (NASDAQ:BLUE) initiated with Hold rating and $42 (13% downside risk) price target by Cantor Fitzgerald.
    • Kite Pharma (NASDAQ:KITE) initiated with Outperform rating and $61 (11% upside) price target by Raymond James.
    • Spark Therapeutics (NASDAQ:ONCE) initiated with Hold rating and $58 (5% upside) price target by Jefferies.
    • Zoetis (NYSE:ZTS) initiated with Buy rating and $58 (21% upside) price target by Stifel Nicolaus.
    • Cardiome Pharma (NASDAQ:CRME) initiated with Buy rating and $9.50 (87% upside) price target by H.C. Wainwright.
    • Premier (NASDAQ:PINC) initiated with Overweight rating and $41 (24% upside) price target by Barclays.
    • Gilead Sciences (NASDAQ:GILD) initiated with Buy rating and $109 (25% upside) price target by Gabelli & Co.
    • Intellia Therapeutics (NASDAQ:NTLA) initiated with Outperform rating and $39 (39% upside) price target by Credit Suisse.
    | Fri, Jun. 3, 8:01 AM | 5 Comments
  • Tue, May 31, 5:37 PM
    | Tue, May 31, 5:37 PM | 1 Comment
  • Thu, May 5, 10:04 AM
    • GW Pharmaceuticals (GWPH -5.3%) fiscal Q2 results (₤M): Revenue: 6.3 (-55.9%); Net Loss: (43.4) (-216.3); Loss Per Share: (13.2p) (-187.0%); CF Ops (6 mo.): (46.4) (-223.8%).
    • Shares are down on light volume.
    | Thu, May 5, 10:04 AM | 1 Comment
  • Thu, May 5, 7:26 AM
    • GW Pharmaceuticals (NASDAQ:GWPH): FQ2 EPS of -₤0.06
    • Revenue of ₤2.65M (-58.3% Y/Y)
    • Press Release
    | Thu, May 5, 7:26 AM | 1 Comment
  • Wed, May 4, 5:30 PM
  • Mon, Apr. 25, 2:06 PM
    • The FDA designates GW Pharmaceuticals' (GWPH -0.9%) Epidiolex (cannabidiol) an Orphan Drug for the treatment of Tuberous Sclerosis Complex (TSC), a rare genetic condition characterized by the formation of non-malignant tumors in different organs that frequently cause seizures.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
    • A Phase 3 study in TSC was initiated earlier this month.
    • Previously: GW Pharma initiates late-stage study of Epidiolex in seizure-characterized genetic disorder (April 11)
    | Mon, Apr. 25, 2:06 PM | 4 Comments
  • Mon, Apr. 11, 3:18 PM
    • GW Pharmaceuticals (GWPH +0.5%) commences a Phase 3 clinical trial assessing lead product candidate Epidiolex (cannabidiol) for the treatment of Tuberous Sclerosis Complex (TSC), a rare genetic condition characterized by formation of non-malignant tumors in different organs. When the tumors form in the brain, they frequent cause seizures, delays in mental development and autism. TSC affects ~50K Americans and ~1M people globally. 80 - 90% of TSC sufferers will develop epilepsy in their lifetimes.
    • The 16-week dose-ranging trial will evaluate Epidiolex against placebo in ~200 subjects. The primary endpoint is the change from baseline in seizure frequency during the treatment period.
    • Epidiolex is currently in late-stage development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, both forms of epilepsy.
    • Read now Soaring Stock Price Of GW Pharma Confirm It As Best Medical Marijuana Play
    | Mon, Apr. 11, 3:18 PM | 3 Comments
Company Description
GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United Kingdom